Admissions Open

Toll Free : 1800 2740 240

The combined effect of cromolyn sodium (mast cell stabilizer) and fenofibrate (PPAR-a agonist) in gentamicin-induced nephropathy has been evaluated. Gentamicin (80mg/kg i.p.) was administered constantly for 8 days to induce nephrotoxicity as a result of activation of mast cell mediators, alteration of lipid profile and initiation of renal oxidative stress. Therefore, its incidence and progression was assessed by biochemical and histopathological examination along with lipid profile and renal oxidative stress. Treatment with cromolyn sodium, Fenofibrate as well as their combination was continued for 10 days in nephrotoxic rats and the parameters were assessed in normal as well as gentamicin-induced rats with or without treatment. The histopathological and biochemical results revealed that treatment with cromolyn sodium (50 mg/kg p.o) prevents the noxious effect of gentamicin by inhibiting mast cell activation and decreasing release of different pro-inflammatory cytokines. A low dose of fenofibrate (32 mg/kg p.o) regulates the distorted lipid profile in gentamicin-induced rats. The combination dose of cromolyn sodium and fenofibrate was more capable in satisfying the gentamicin-induced nephropathy and renal oxidative stress when compared with either standard drug lisinopril (1 mg/kg p.o.) or drug alone. Combination of cromolyn sodium with fenofibrate can be used as an effective nephroprotective approach to treat the gentamicin induced nephropathy.

Admission Enquiry 2020

Skip to content Skip to content